In contrast, higher doses (up to 7.5 mg/m2) were found to be very effective and tolerable in children and adolescents with poor-risk CD33 + AML, when GO was added to a busulfan/cyclophosphamide conditioning regimen before allo-HCT [70]. Here, CD33 is linked to acute myeloid leukemia.